Virtual Reality Distracts Kids During Chemo

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

ATLANTA-Pediatric cancer patients often have anxiety before scheduled treatments or procedures, and treatment often requires normally active children to remain nearly motionless for extended periods of time. At the AFLAC Cancer Center at Children’s Healthcare of Atlanta, young cancer patients may find their treatment a little easier to bear thanks to an innovative program currently under way to examine the effects of virtual reality as a “distractor” for painful or uncomfortable medical procedures.

ATLANTA—Pediatric cancer patients often have anxiety before scheduled treatments or procedures, and treatment often requires normally active children to remain nearly motionless for extended periods of time. At the AFLAC Cancer Center at Children’s Healthcare of Atlanta, young cancer patients may find their treatment a little easier to bear thanks to an innovative program currently under way to examine the effects of virtual reality as a “distractor” for painful or uncomfortable medical procedures.

The research was conceived by psychologist Dr. Barbara Rothbaum of Emory University and computer expert Dr. Larry Hodges of the Georgia Institute of Technology, founders of Virtually Better, Inc.

The anecdotal evidence is promising so far, according to Rosemarie Lemos, a registered nurse with the Outpatient Clinic at the AFLAC Cancer Center. “One very anxious patient, as he was experiencing the virtual reality environment, asked me when I was going to perform the procedure,” she said. “My response was ‘I already did.’”

The initial study of the virtual reality system includes 50 patients between the ages of 8 and 18 undergoing chemotherapy via a central venous access device.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content